文献速递肿瘤 PET/CT

淋巴瘤治疗超早期反应评估:[18F]FDG PET/MR可捕捉治疗开始72小时内的葡萄糖代谢与细胞密度变化

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-26

这项前瞻性IRB批准研究纳入58例淋巴瘤患者(11例霍奇金淋巴瘤、47例非霍奇金淋巴瘤,共166个病灶),在治疗前、治疗开始后48-72小时(FU-1)及1周(FU-2)行[18F]FDG PET/MR。结果显示,与基线相比,FU-1时SUVmax、SUVmean、ADCmin、ADCmean、MTV和VOL的平均变化率分别为-46.8%、-33.3%、+20.3%、+14%、-46%和-12.8%,除FU-1时VOL变化(P=0.079)外均具有统计学显著性(P<0.01)。结论认为[18F]FDG PET/MR可在治疗开始后48-72小时捕捉淋巴瘤治疗引起的葡萄糖代谢和细胞密度变化。

要点

  • 58例淋巴瘤患者(11例霍奇金、47例非霍奇金)共166个病灶纳入分析。
  • 治疗开始后48-72小时,SUVmax平均变化率为-46.8%,ADCmin为+20.3%,MTV为-46%。
  • FU-1时VOL变化(-12.8%)未达统计学显著(P=0.079),其余指标变化均P<0.01。

核心结论

  • 在淋巴瘤患者中,[18F]FDG PET/MR可在治疗开始后48-72小时捕捉治疗引起的葡萄糖代谢和细胞密度变化。

研究设计与样本

  • 前瞻性IRB批准研究,纳入组织学证实的霍奇金淋巴瘤或非霍奇金淋巴瘤患者,共58例(11例霍奇金淋巴瘤、47例非霍奇金淋巴瘤),166个病灶。
  • 患者在治疗前、第一周期标准化疗(霍奇金淋巴瘤)或免疫化疗(非霍奇金淋巴瘤)开始后48-72小时(FU-1)及1周(FU-2)行[18F]FDG PET/MR。
  • 在每个时间点评估标准化[18F]FDG摄取值(SUVmax、SUVmean)、基于弥散加权MRI的表观弥散系数(ADCmin、ADCmean)以及代谢和形态学肿瘤体积(MTV、VOL)。
  • 采用非结构化协方差矩阵的多水平分析和配对事后检验比较三个时间点间SUVs、ADCs、MTVs和VOLs的显著变化。

主要发现

  • 基线至FU-1,基于病灶的SUVmax、SUVmean、ADCmin、ADCmean、MTV和VOL平均变化率分别为-46.8%、-33.3%、+20.3%、+14%、-46%和-12.8%。
  • 基线至FU-2,基于病灶的SUVmax、SUVmean、ADCmin、ADCmean、MTV和VOL平均变化率分别为-65.1%、-49%、+50.7%、+32.4%、-61.1%和-24.2%。
  • 上述变化除基线至FU-1的VOL变化(P=0.079)外均具有统计学显著性(P<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether, in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), [18F]FDG PET/MR can capture treatment effects within the first week after treatment initiation, and whether changes in glucose metabolism and cell density occur simultaneously. METHODS: Patients with histologically proven HL or NHL were included in this prospective IRB-approved study. Patients underwent [18F]FDG PET/MR before, and then 48-72 h after (follow-up 1, FU-1) and 1 week after (FU-2) initiation of the first cycle of their respective standard chemotherapy (for HL) or immunochemotherapy (for NHL). Standardized [18F]FDG uptake values (SUVmax, SUVmean) and apparent diffusion coefficients (ADCmin, ADCmean) based on diffusion-weighted MRI, and metabolic and morphological tumour volumes (MTV, VOL) were assessed at each time-point. Multilevel analyses with an unstructured covariance matrix, and pair-wise post-hoc tests were used to test for significant changes in SUVs, ADCs, MTVs and VOLs between the three time-points. RESULTS: A total of 58 patients (11 with HL and 47 with NHL) with 166 lesions were analysed. Lesion-based mean rates of change in SUVmax, SUVmean, ADCmin, ADCmean, MTV and VOL between baseline and FU-1 were -46.8%, -33.3%, +20.3%, +14%, -46% and -12.8%, respectively, and between baseline and FU-2 were -65.1%, -49%, +50.7%, +32.4%, -61.1% and -24.2%, respectively. These changes were statistically significant (P < 0.01) except for the change in VOL between baseline and FU-1 (P = 0.079). CONCLUSION: In lymphoma patients, [18F]FDG PET/MR can capture treatment-induced changes in glucose metabolism and cell density as early as 48-72 h after treatment initiation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mayerhoefer ME, Raderer M, Jaeger U, et al. Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. Eur J Nucl Med Mol Imaging. 2018. PMID: 29480328. doi:10.1007/s00259-018-3937-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。